TAAR1 and psychotic disorder: This was recently supported by a 4-week phase-II trial, where ulotaront (SEP-363856), an agonist of TAAR1 and the serotonin 1A receptor (5-HT1AR) with a negligible binding affinity to dopaminergic receptor, was found to be more efficacious than placebo in reducing overall symptoms of psychosis in individuals with acute schizophrenia while avoiding common side effects such as weight gain and movement disorders.